C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Yorrick R J Jaspers1, Inge M E Dijkstra1, Marc Engelen2

  • 1Laboratory Genetic Metabolic Diseases, Department of Laboratory Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam Neuroscience, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands.

Summary

X-linked adrenoleukodystrophy (ALD) is diagnosed using C26:0-lysophosphatidylcholine (LPC(26:0)), a marker that also predicts disease severity and aids in monitoring treatment effectiveness. This biomarker offers improved accuracy over traditional methods.